YPSN Stock Overview
Develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Ypsomed Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 359.50 |
| 52 Week High | CHF 439.00 |
| 52 Week Low | CHF 261.00 |
| Beta | 1.01 |
| 1 Month Change | 9.77% |
| 3 Month Change | -7.23% |
| 1 Year Change | 16.34% |
| 3 Year Change | 110.23% |
| 5 Year Change | 148.96% |
| Change since IPO | 385.81% |
Recent News & Updates
We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt
Jan 23
Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
Jan 09Returns On Capital Are Showing Encouraging Signs At Ypsomed Holding (VTX:YPSN)
Dec 23Recent updates
We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt
Jan 23Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
Jan 09Returns On Capital Are Showing Encouraging Signs At Ypsomed Holding (VTX:YPSN)
Dec 23We Think That There Are Some Issues For Ypsomed Holding (VTX:YPSN) Beyond Its Promising Earnings
Nov 20Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Interim Results
Nov 17Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
Aug 13There Are Reasons To Feel Uneasy About Ypsomed Holding's (VTX:YPSN) Returns On Capital
Jul 31If EPS Growth Is Important To You, Ypsomed Holding (VTX:YPSN) Presents An Opportunity
Jul 03Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise
Jun 19Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF395?
Jun 10Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Full-Year Results
May 25Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
May 08Investors Could Be Concerned With Ypsomed Holding's (VTX:YPSN) Returns On Capital
Apr 07Is There Now An Opportunity In Ypsomed Holding AG (VTX:YPSN)?
Mar 09Here's Why We Think Ypsomed Holding (VTX:YPSN) Might Deserve Your Attention Today
Feb 07Shareholder Returns
| YPSN | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 0.7% | 2.9% | 2.3% |
| 1Y | 16.3% | 13.7% | 10.2% |
Return vs Industry: YPSN exceeded the Swiss Medical Equipment industry which returned 13.7% over the past year.
Return vs Market: YPSN exceeded the Swiss Market which returned 10.2% over the past year.
Price Volatility
| YPSN volatility | |
|---|---|
| YPSN Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 4.0% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 8.3% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: YPSN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: YPSN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,600 | Simon Michel | www.ypsomed.com |
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices.
Ypsomed Holding AG Fundamentals Summary
| YPSN fundamental statistics | |
|---|---|
| Market cap | CHF 4.93b |
| Earnings (TTM) | CHF 74.39m |
| Revenue (TTM) | CHF 617.07m |
66.0x
P/E Ratio8.0x
P/S RatioIs YPSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YPSN income statement (TTM) | |
|---|---|
| Revenue | CHF 617.07m |
| Cost of Revenue | CHF 398.41m |
| Gross Profit | CHF 218.66m |
| Other Expenses | CHF 144.28m |
| Earnings | CHF 74.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
May 21, 2025
| Earnings per share (EPS) | 5.45 |
| Gross Margin | 35.44% |
| Net Profit Margin | 12.05% |
| Debt/Equity Ratio | 52.3% |
How did YPSN perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 19:08 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ypsomed Holding AG is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Curtis Moiles | BNP Paribas Exane |
| Thomas Bernhardsgrutter | CA Cheuvreux |